摘要 |
<p>The invention relates to pharmaceutical agents containing a particulate inorganic matrix having a diameter of from 0.1 nm to 100 µm, preferably 1 nm to 10 µm, particularly preferably 1 nm to 1 µm, such as, for example, topaz, (Al2F2)[SiO4], and chiolite, Na[Al3F4], preferably wavellite, Al3(PO4)2(OH, F)2, calcium carbonate, CaCO3, maghemite, Y-Fe2O3, particularly preferably zeolites, gen. formula Mn[(AlO2)x(SiO2)y](M = metal, e.g. Na), magnetite, Fe3O4, and barium sulphate, BaSO4, and very particularly preferably gallium phosphate, GaPO4, apatite or fluorohydroxyapatite, Ca5(PO4)3(OH, F) = 3Ca3(PO4)2 * Ca(OH, F)2, and fluorspar, CaF2, which, in addition to the natural isotope distribution of the structure type--forming elements of the anions and cations, also contain medically usable contents of positron-emitting nuclides, such as, for example, [15]O, [30]P, [13]N, preferably [65]Ga, [11]C, particularly preferably [131]Ba, [26]Al, and very particularly preferably [68]Ga and [18]F, the preparation thereof, and the use of these composition in medicine, particularly preferably in diagnostic imaging, in particular positron emission tomography (PET), on animals and humans, and in vitro diagnostics.</p> |